![Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP). - ScienceDirect Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP). - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497119753828-fx1.jpg)
Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP). - ScienceDirect
![CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP | Journal of Clinical Oncology CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2016/jco.2015.64.34.issue-26/jco.2015.65.6520/20161107/images/medium/jco656520t2.gif)
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP | Journal of Clinical Oncology
![Table 1 from ANALYSIS OF PROGNOSTIC FACTORS IN HODGKIN ' S LYMPHOMA WITH REGARD TO RESPONSE TO TREATMENT | Semantic Scholar Table 1 from ANALYSIS OF PROGNOSTIC FACTORS IN HODGKIN ' S LYMPHOMA WITH REGARD TO RESPONSE TO TREATMENT | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/78d05595108cef38c91ed890efd46ddcd1594d2d/2-Table1-1.png)
Table 1 from ANALYSIS OF PROGNOSTIC FACTORS IN HODGKIN ' S LYMPHOMA WITH REGARD TO RESPONSE TO TREATMENT | Semantic Scholar
![Table 1 from An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. | Semantic Scholar Table 1 from An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5835aee9687d11160fd503ad0ecb876e36789aca/3-Table1-1.png)
Table 1 from An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. | Semantic Scholar
![Kyle Bradley, MD on Twitter: "@KyleBradleyMD CLL-IPI score = sum of grades for the 5 prognostic parameters." / Twitter Kyle Bradley, MD on Twitter: "@KyleBradleyMD CLL-IPI score = sum of grades for the 5 prognostic parameters." / Twitter](https://pbs.twimg.com/media/CnqX1jgWgAAteoZ.jpg)
Kyle Bradley, MD on Twitter: "@KyleBradleyMD CLL-IPI score = sum of grades for the 5 prognostic parameters." / Twitter
![Table 2 from The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar Table 2 from The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0ce5e3433e7e5c0a7252094d6a23f65336327517/3-Table2-1.png)
Table 2 from The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar
![CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP | Journal of Clinical Oncology CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2016/jco.2015.64.34.issue-26/jco.2015.65.6520/20161107/images/medium/jco656520ta1.gif)